Teleflex to Support Responding to Cardiac Arrest at ERC Congress, Resuscitation 2018, in Bologna, Italy from September 20th – 22nd
Cardiac Arrest is one of the leading causes of mortality with an estimated 10% survival rate.1 2
Prompt treatment is essential for all cardiac arrest patients, whether a
patient suffers an in-hospital cardiac arrest (IHCA) or an
out-of-hospital cardiac arrest (OHCA). Studies have found an incidence
rate of 84 OHCA per 100,000 population 2 and between
1.51-2.85 IHCA per 1.000 hospital patient admissions.3,4 The
incidence of cardiac arrest is a major health problem within
When a cardiac arrest occurs, rapid delivery of fluids and medication is key to treatment. Clinicians need fast methods of establishing vascular access, and IV access may be difficult or impossible due to cardiovascular collapse and environmental challenges.
The Arrow® EZ-IO® Intraosseous Vascular Access
While ERC is taking place,
Moreover, in collaboration with the
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
Mozaffarian D, Benjamin EJ, Go AS, et al: on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322. DOI: 10.1161/CIR.0000000000000152.
|2.||EuReCa ONE 27 Nations, ONE Europe, ONE Registry: A prospective one month analysis of out-of-hospital cardiac arrest outcomes in 27 countries in Europe, Volume 105, August 2016, Pages 188-195|
|3.||Incidence and outcome of in-hospital cardiac arrest in Italy: a multicentre observational study in the Piedmont Region, Resuscitation [24 Jun 2017, 119:48-55]|
|4.||Public Report Cards for In-Hospital Cardiac Arrest: Empowering the Public With Location-Specific Data, Circulation. Author manuscript; available in PMC 2016 Apr 21|
|5.||Davidoff J, Fowler R, Gordon D, Klein G, Kovar J, Lozano M, Potkya J, Racht E, Saussy J, Swanson E, Yamada R, Miller L. Clinical evaluation of a novel intraosseous device for adults: prospective, 250-patient, multi-center trial. JEMS 2005;30(10):s20-3. Research sponsored by Teleflex Incorporated.|
|6.||Montez D, Puga T, Miller LJ, et al. Intraosseous Infusions from the Proximal Humerus Reach the Heart in Less Than 3 Seconds in Human Volunteers. Annals of Emergency Medicine 2015;66(4S):S47. Research sponsored by Teleflex Incorporated.|
Cooper BR, Mahoney PF, Hodgetts TJ, Mellor A. Intra-osseous access (EZ-IO®) for resuscitation: UK military combat experience. J R Army Med Corps. 2007;153(4):314-31 *, **
|8.||Teleflex Internal Data on file 2018|
|9.||Hoskins SL, Nascimento P Jr., Lima RM, Espana-Tenorio, JM, Kramer GC. Pharmacokinetics of intraosseous and central venous drug delivery during cardiopulmonary resuscitation. Resuscitation 2011; doi:10.1016/j.resuscitation.2011.07.041. Research sponsored by Teleflex Incorporated. (preclinical study) *, **|
Hoskins SL, Zachariah BS, Copper N, Kramer GC. Comparison of intraosseous proximal humerus and sternal routes for drug delivery during CPR. Circulation 2007; 116:II_993. Research sponsored by Teleflex Incorporated. (preclinical study) *, **
*Compared to single lumen Central Venous Catheters (CVCs).
**Based on Adult Proximal Humerus EZ-IO® insertion data.
Treasurer and Vice President, Investor Relations